View in EDS HTML Full Text PDF Full Text

IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.

Saved in:
Bibliographic Details
Title: IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.
Authors: Yosifov DY; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.; German Cancer Research Center (DKFZ) Heidelberg Germany., Robrecht S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany., Giza A; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany., Maity PC; Institute of Experimental Cancer Research Ulm University Medical Center Ulm Germany., Riecke A; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.; Internal Medicine, Division of Hematology German Military Hospital Ulm Ulm Germany., Schneider C; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.; Comprehensive Cancer Center Ulm (CCCU) Ulm University Hospital Ulm Germany., Jebaraj BMC; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany., Dheenadayalan RP; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany., Jumaa H; Institute of Immunology Ulm University Hospital Ulm Germany., Young M; Institute of Immunology Ulm University Hospital Ulm Germany., Kumar M; Institute of Experimental Cancer Research Ulm University Medical Center Ulm Germany., Müller L; Study Centrum Unter Ems Practice for Oncology and Hematology Leer Germany., Vehling-Kaiser U; Outpatient Clinic Landshut Germany., Eckart M; Onkologische Schwerpunktpraxis Erlangen Erlangen Germany., Freier W; Medicinum Hildesheim Germany., Schöttker B; Hämatologisch-onkologische Schwerpunktpraxis Würzburg Würzburg Germany., Gaska T; Brüderkrankenhaus St. Josef Paderborn Germany., Reiser M; Praxis Internistischer Onkologie und Hämatologie Frechen Germany., Fink AM; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany., Fischer K; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany., Eichhorst B; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany., Hallek M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany., Langerbeins P; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany., Tausch E; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.; Comprehensive Cancer Center Ulm (CCCU) Ulm University Hospital Ulm Germany., Stilgenbauer S; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.; Comprehensive Cancer Center Ulm (CCCU) Ulm University Hospital Ulm Germany.
Source: HemaSphere [Hemasphere] 2026 Jun 15; Vol. 10 (6), pp. e70385. Date of Electronic Publication: 2026 Jun 15 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42306064
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: IGLV3-21<superscript>R110</superscript> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yosifov+DY%22">Yosifov DY</searchLink>; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.; German Cancer Research Center (DKFZ) Heidelberg Germany.<br /><searchLink fieldCode="AU" term="%22Robrecht+S%22">Robrecht S</searchLink>; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany.<br /><searchLink fieldCode="AU" term="%22Giza+A%22">Giza A</searchLink>; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany.<br /><searchLink fieldCode="AU" term="%22Maity+PC%22">Maity PC</searchLink>; Institute of Experimental Cancer Research Ulm University Medical Center Ulm Germany.<br /><searchLink fieldCode="AU" term="%22Riecke+A%22">Riecke A</searchLink>; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.; Internal Medicine, Division of Hematology German Military Hospital Ulm Ulm Germany.<br /><searchLink fieldCode="AU" term="%22Schneider+C%22">Schneider C</searchLink>; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.; Comprehensive Cancer Center Ulm (CCCU) Ulm University Hospital Ulm Germany.<br /><searchLink fieldCode="AU" term="%22Jebaraj+BMC%22">Jebaraj BMC</searchLink>; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.<br /><searchLink fieldCode="AU" term="%22Dheenadayalan+RP%22">Dheenadayalan RP</searchLink>; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.<br /><searchLink fieldCode="AU" term="%22Jumaa+H%22">Jumaa H</searchLink>; Institute of Immunology Ulm University Hospital Ulm Germany.<br /><searchLink fieldCode="AU" term="%22Young+M%22">Young M</searchLink>; Institute of Immunology Ulm University Hospital Ulm Germany.<br /><searchLink fieldCode="AU" term="%22Kumar+M%22">Kumar M</searchLink>; Institute of Experimental Cancer Research Ulm University Medical Center Ulm Germany.<br /><searchLink fieldCode="AU" term="%22Müller+L%22">Müller L</searchLink>; Study Centrum Unter Ems Practice for Oncology and Hematology Leer Germany.<br /><searchLink fieldCode="AU" term="%22Vehling-Kaiser+U%22">Vehling-Kaiser U</searchLink>; Outpatient Clinic Landshut Germany.<br /><searchLink fieldCode="AU" term="%22Eckart+M%22">Eckart M</searchLink>; Onkologische Schwerpunktpraxis Erlangen Erlangen Germany.<br /><searchLink fieldCode="AU" term="%22Freier+W%22">Freier W</searchLink>; Medicinum Hildesheim Germany.<br /><searchLink fieldCode="AU" term="%22Schöttker+B%22">Schöttker B</searchLink>; Hämatologisch-onkologische Schwerpunktpraxis Würzburg Würzburg Germany.<br /><searchLink fieldCode="AU" term="%22Gaska+T%22">Gaska T</searchLink>; Brüderkrankenhaus St. Josef Paderborn Germany.<br /><searchLink fieldCode="AU" term="%22Reiser+M%22">Reiser M</searchLink>; Praxis Internistischer Onkologie und Hämatologie Frechen Germany.<br /><searchLink fieldCode="AU" term="%22Fink+AM%22">Fink AM</searchLink>; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany.<br /><searchLink fieldCode="AU" term="%22Fischer+K%22">Fischer K</searchLink>; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany.<br /><searchLink fieldCode="AU" term="%22Eichhorst+B%22">Eichhorst B</searchLink>; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany.<br /><searchLink fieldCode="AU" term="%22Hallek+M%22">Hallek M</searchLink>; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany.<br /><searchLink fieldCode="AU" term="%22Langerbeins+P%22">Langerbeins P</searchLink>; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany.<br /><searchLink fieldCode="AU" term="%22Tausch+E%22">Tausch E</searchLink>; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.; Comprehensive Cancer Center Ulm (CCCU) Ulm University Hospital Ulm Germany.<br /><searchLink fieldCode="AU" term="%22Stilgenbauer+S%22">Stilgenbauer S</searchLink>; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.; Comprehensive Cancer Center Ulm (CCCU) Ulm University Hospital Ulm Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101740619%22">HemaSphere</searchLink> [Hemasphere] 2026 Jun 15; Vol. 10 (6), pp. e70385. <i>Date of Electronic Publication: </i>2026 Jun 15 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101740619 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2572-9241 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225729241%22">25729241 </searchLink><i>NLM ISO Abbreviation: </i>Hemasphere <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42306064
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/hem3.70385
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e70385
    Titles:
      – TitleFull: IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yosifov DY
      – PersonEntity:
          Name:
            NameFull: Robrecht S
      – PersonEntity:
          Name:
            NameFull: Giza A
      – PersonEntity:
          Name:
            NameFull: Maity PC
      – PersonEntity:
          Name:
            NameFull: Riecke A
      – PersonEntity:
          Name:
            NameFull: Schneider C
      – PersonEntity:
          Name:
            NameFull: Jebaraj BMC
      – PersonEntity:
          Name:
            NameFull: Dheenadayalan RP
      – PersonEntity:
          Name:
            NameFull: Jumaa H
      – PersonEntity:
          Name:
            NameFull: Young M
      – PersonEntity:
          Name:
            NameFull: Kumar M
      – PersonEntity:
          Name:
            NameFull: Müller L
      – PersonEntity:
          Name:
            NameFull: Vehling-Kaiser U
      – PersonEntity:
          Name:
            NameFull: Eckart M
      – PersonEntity:
          Name:
            NameFull: Freier W
      – PersonEntity:
          Name:
            NameFull: Schöttker B
      – PersonEntity:
          Name:
            NameFull: Gaska T
      – PersonEntity:
          Name:
            NameFull: Reiser M
      – PersonEntity:
          Name:
            NameFull: Fink AM
      – PersonEntity:
          Name:
            NameFull: Fischer K
      – PersonEntity:
          Name:
            NameFull: Eichhorst B
      – PersonEntity:
          Name:
            NameFull: Hallek M
      – PersonEntity:
          Name:
            NameFull: Langerbeins P
      – PersonEntity:
          Name:
            NameFull: Tausch E
      – PersonEntity:
          Name:
            NameFull: Stilgenbauer S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 06
              Text: 2026 Jun 15
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2572-9241
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: HemaSphere
              Type: main
ResultId 1